硼替佐米在多发性骨髓瘤伴肾功能损害患者的应用

发布时间：2018-04-19 00:08

  本文选题：硼替佐米 + 多发性骨髓瘤　； 参考：《肾脏病与透析肾移植杂志》2017年03期

【摘要】：正多发性骨髓瘤(MM)是来源于浆细胞克隆性增殖的血液系统恶性肿瘤。骨髓瘤细胞可分泌大量单克隆免疫球蛋白或其片段(M蛋白),临床上常表现贫血、骨痛、溶骨性破坏、肾功能损害、反复感染等,目前仍无法治愈。初诊的MM患者中,20%~28.2%存在肾功能损害(renal impairment,RI)[血清肌酐水平177μmol/L或2 mg/dl,或估算肾小球滤过率(eGFR)≤50
[Abstract]:Multiple myeloma (MMM) is a hematological malignant tumor derived from the clonal proliferation of plasma cells.Myeloma cells can secrete a large number of monoclonal immunoglobulin or its fragment of M protein, the clinical manifestations of anemia, bone pain, osteolytic destruction, renal function damage, repeated infection and so on, is still incurable.28. 2% of newly diagnosed MM patients have renal impairment renal impairmentRI [serum creatinine level 177 渭 mol/L or 2 mg / dl, or estimated glomerular filtration rate] 鈮，

本文编号：1770685